TRIL

Trillium Therapeutics Inc.
TRIL

Overview Fund Activity
Delisted

TRIL was delisted on the 16th of November, 2021.

Back to rankings

29 hedge funds and large institutions have $27.6M invested in Trillium Therapeutics Inc. in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 6 closing their positions.

Holders
29
Holders Change
–
Holders Change %
0%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
NLVP
1
New Leaf Venture Partners
New York
$725K
2
EAM
2
EverPoint Asset Management
Connecticut
$1.94M
3
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$3.32M
4
ECM
4
Endurant Capital Management
California
$245K
5
KPF
5
K2 Principal Fund
Ontario, Canada
$131K

Top Sellers

1
Millennium Management
1
Millennium Management
New York
$1.03M
2
OAM
2
Oxford Asset Management
United Kingdom
$855K
3
JHIU
3
Janus Henderson Investors US
Colorado
$5.09M
4
PA
4
Perceptive Advisors
New York
$0
5
Renaissance Technologies
5
Renaissance Technologies
New York
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Royal Bank of Canada
26
Royal Bank of Canada
Ontario, Canada
$1K -$349 -37 -26%
UBS Group
27
UBS Group
Switzerland
$1K +$1K +166 New
PA
28
Perceptive Advisors
New York
– -$278K -30,000 Closed
Renaissance Technologies
29
Renaissance Technologies
New York
– -$236K -25,478 Closed
PCA
30
Private Capital Advisors
Connecticut
– -$231K -25,000 Closed
SM
31
Sabby Management
Florida
– -$131K -14,137 Closed
Morgan Stanley
32
Morgan Stanley
New York
– -$45K -4,889 Closed
JPMorgan Chase & Co
33
JPMorgan Chase & Co
New York
– -$32K -3,505 Closed
1
2